Epidemiological patterns of pulmonary hypertension at 3,658 meters: insights from a Tibet plateau retrospective study Authors: Quzhen Gesang, Zhuoga Danzeng, Yangzong Suona, Qin Luo, Qucuo Meilang, Ciren Dawa, Zhuoga Baima, Ju Huang, Luobu Gesang Published: 2026 ABSTRACT AbstractBackgroundHigh altitude environment exerts a significant impact on the pathophysiology of various types of pulmonary hypertension, yet the clinical characteristics of pulmonary hypertension in high altitude areas remain unclear. The purpose of this study was to clarify the type distribution and clinical features of pulmonary hypertension in high-altitude regions.MethodsA retrospective study was conducted. Consecutive inpatients who underwent complete Doppler echocardiography and were diagnosed with pulmonary hypertension at the People’s Hospital of Xizang Autonomous Region from January 2014 to January 2019 were enrolled. Their demographic data, etiological information, laboratory indicators and echocardiographic parameters were collected. Patients were divided into five groups according to clinical classification criteria, and the differences among the groups were compared.ResultsA total of 312 patients with pulmonary hypertension were enrolled, with a mean age of 60±14 years, including 164 males (52.6%) and 148 females (47.4%). The subjects were predominantly of Zang ethnicity (295 cases, 94.6%), with a mean residential altitude of 3,865±409 meters. According to the World Health Organization (WHO) clinical classification, Group 3 accounted for the highest proportion (66.0%), followed by Group 2 (16.0%), Group 1 (12.8%), Group 5 (2.9%) and Group 4 (2.2%). The main etiologies were chronic obstructive pulmonary disease (COPD)/emphysema (31.1%) and high altitude pulmonary hypertension (HAPH) (29.5%). Patients in Group 3 had the highest proportion of males (62.1%), the oldest age and the highest smoking rate (39.8%), and their hemoglobin, hematocrit and red blood cell count were significantly higher than those in other groups (all P<0.01).ConclusionsGroup 3 is the most common type of pulmonary hypertension in hospitalized patients in high-altitude areas, with the main etiologies being COPD/emphysema and HAPH.Keywords: Pulmonary hypertension (PH), high altitude, high altitude pulmonary hypertension (HAPH) Highlight box Key findings • Group 3 pulmonary hypertension (PH) dominated in high-altitude regions (66.0%), mainly caused by chronic obstructive pulmonary disease/emphysema and high altitude pulmonary hypertension (HAPH). • Group 3 patients had higher hemoglobin, hematocrit and red blood cell levels. • Male preponderance. What is known and what is new? • Group 2 PH is most common in lowlands; hypoxia drives PH. • First report on PH spectrum in high-altitude areas, confirming the dominance of Group 3 PH. What is the implication, and what should change now? • Provides scientific basis for precise classification, etiology and diagnosis of PH at high altitude. • Hypoxic environment plays an important role in the pathogenesis of pulmonary hypertension. Introduction Pulmonary hypertension (PH) is a pathophysiological syndrome characterized by a progressive increase in pulmonary vascular resistance, which can eventually lead to right heart failure and even death. Approximately 1% of the global population is affected by PH, and it has long been a difficult and hot topic in cardiovascular research due to its complex etiology and poor prognosis (1). Based on etiological and pathophysiological characteristics, the World Health Organization (WHO) classifies PH into five major clinical categories, which has become a core framework guiding clinical diagnosis, treatment and research. Despite advances in PH diagnosis and treatment technologies in recent years, the clinical characteristics and management strategies of PH in high-altitude areas remain to be further investigated. The hypoxic environment at high altitudes is an important predisposing factor for the development and progression of PH. Chronic hypoxia activates the hypoxia-inducible factor-1α (HIF-1α) pathway to promote the proliferation of pulmonary arterial smooth muscle cells, leading to irreversible vascular wall thickening. This induces pulmonary vasoconstriction, endothelial dysfunction and vascular remodeling, which in turn results in elevated pulmonary arterial pressure (2,3). In addition, chronic hypoxia can cause multisystem damage by activating oxidative stress and inflammatory responses, and it is closely associated with an increased risk of complications such as left heart disease and thromboembolism (4-6). Approximately 81.6 million humans live at ≥2,500 meters for a long time (7), and the prevalence of high altitude pulmonary hypertension (HAPH) is about 6.2–12% (8,9). Uncovering the disease characteristics of high altitude PH is of great public health significance for improving the health management level of populations residing in high-altitude areas. Previous studies on PH in high-altitude regions have mainly focused on populations living below 3,000 meters with a single etiological spectrum, centering on chronic obstructive pulmonary disease (COPD)-associated PH and HAPH without covering other types classified by the WHO PH criteria (10-13), thus failing to fully reveal the regular patterns of PH classification and phenotypic characteristics in the high-altitude environment. As the region with the highest average altitude in the world (>4,000 meters), Xizang has an atmospheric oxygen partial pressure of only 60% of that at sea level, providing a unique study population for investigating hypoxic PH. By integrating demographic, clinical and etiological data, this study aims to clarify the classification characteristics, etiological composition and clinical manifestations of PH in high-altitude environments, in order to enhance the specificity and accuracy of clinical treatment for this disease, and to provide a scientific basis for individualized diagnosis, treatment and health management of pulmonary hypertension in high-altitude regions. We present this article in accordance with the STROBE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0412/rc). Methods Patients and study design This study was a single-center retrospective study conducted at the Xizang Autonomous Region People’s Hospital, located at an altitude of 3,658 meters. The number of inpatients in this hospital accounts for 25% of the total inpatients in tertiary hospitals on the Xizang Plateau [The 2019 Hospital Service Statistics Report of the Health Commission of Xizang Autonomous Region (14)], rendering the study sample representative to a certain extent. A total of 312 consecutive inpatients who underwent transthoracic echocardiography and were diagnosed with pulmonary hypertension (PH) in the hospital from January 2014 to January 2019 were enrolled. The patients were included in the study in accordance with the following diagnostic criteria: (I) HAPH was diagnosed in accordance with the 2004 Criteria for Diagnosis of High Altitude Pulmonary Hypertension, Simultaneous fulfillment of all the following criteria: (i) long-term residence at an altitude ≥2,500 m for ≥5 years; (ii) echocardiographically estimated systolic pulmonary artery pressure (sPAP) >50 mmHg (sPAP was estimated based on the peak velocity of tricuspid regurgitation measured by echocardiography); and (III) exclusion of all other known causes of PH, including COPD, left heart disease, connective tissue disease, congenital heart disease, and chronic thromboembolic pulmonary hypertension, etc. (8); this study adopted the high altitude specific diagnostic criteria for the following reasons: (I) this was a retrospective study conducted from 2014 to 2019, during which the Right Heart Catheterization (RHC) based diagnostic system for HAPH had not been routinely implemented in this region; (II) high-altitude residents usually present with elevated hematocrit and increased blood viscosity, which may lead to falsely elevated pulmonary artery pressure measurements. Therefore, specific diagnostic thresholds tailored for high-altitude populations were applied in the present study. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Medical Ethics Committee of Xizang Autonomous Region People’s Hospital (No. ME-TBHP-25-KJ-050) and individual consent for this retrospective analysis was waived. In patients diagnosed with HAPH, the measured sPAP was corrected. Due to the lack of invasively measured mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), cardiac output (CO), and pulmonary artery wedge pressure (PAWP), standardized reference values were assumed for the calculation: COstd =4.5 L/min and PAWPstd=10 mmHg. These standardized values were used to eliminate the confounding effect of hematocrit variability on the estimation of pulmonary vascular pressures, according to the empirical formula proposed by Chemla et al. [2004] (15), sPAP was used to estimate mPAP: mPAP = 0.61 × sPAP + 2 mmHg. The standardized PVR (PVRstd) was calculated for each patient under the conditions of standardized CO and PAWP: PVRstd =(mPAP− PAWPstd)/COstd, The correction factor for blood viscosity effects on PVR was then calculated using a reference hematocrit value of 45%:ηratio = e0.028 × (45 − HCT) (16,17), Standardized PVR was combined with the blood viscosity correction coefficient to recalculate the corrected mPAP, with the formula expressed as: mPAPcorr = PVRstd × ηratio × COstd + PAWPstd. This approach enables a reasonable estimation of pulmonary arterial pressure in the absence of measured RHC data, by fixing standardized CO and PAWP and performing hematocrit-based correction. PH of other types was diagnosed in accordance with the 2025 American Society of Echocardiography (ASE) criteria, with a transthoracic echocardiographic estimated sPAP ≥35 mmHg (18); (II) inpatients aged ≥18 years; (III) patients with complicated severe cardiovascular and cerebrovascular diseases, malignant tumors or systemic neurological diseases were excluded; (IV) patients with a residential history of less than 5 years at an altitude of 2,500 meters and above were excluded. Demographic characteristics, clinical manifestations, blood test indicators and echocardiographic data of the enrolled patients were collected. All patients were classified into five groups in accordance with the WHO PH classification criteria: Group 1 (pulmonary arterial hypertension, PAH), Group 2 (pulmonary hypertension due to left heart disease), Group 3 (pulmonary hypertension due to lung diseases and/or hypoxia), Group 4 (chronic thromboembolic pulmonary hypertension, CTEPH), and Group 5 (pulmonary hypertension with unclear and multifactorial mechanisms), with subsequent comparative analysis conducted among the groups. Transthoracic echocardiography The study used a Philips EPIQ7 echocardiography diagnostic system. Conventional two-dimensional and color Doppler methods were combined to obtain left ventricular end-diastolic diameter, left ventricular ejection fraction, left ventricular fractional shortening, left ventricular posterior wall thickness, interventricular septum thickness, left atrial anteroposterior diameter, right ventricular anterior wall thickness, right ventricular internal diameter, right ventricular outflow tract diameter, and valve morphology and blood flow conditions. Pulmonary artery systolic pressure was calculated using the formula: Pulmonary artery systolic pressure = 4 (VTR)2 + C, where VTR is the peak tricuspid regurgitation velocity measured by continuous Doppler echocardiography, and C is the estimated right atrial pressure (5–15 mmHg) based on right atrial size, inferior vena cava width, and inspiratory collapse rate (1 mmHg = 0.133 kPa). Statistical analysis All statistical analyses were performed using R software (version 3.6.5). All statistical tests were two-sided, with P≤0.05 considered statistically significant. Normality of continuous variables was assessed using the Shapiro-Wilk test. Normally distributed data were presented as mean ± standard deviation, while non-normally distributed data were presented as median (P25, P75). Multiple imputation was used for missing data to reduce bias. For multiple group comparisons, one-way analysis of variance (ANOVA) was used for normally distributed continuous variables, and Kruskal-Wallis H test was used for non-normally distributed continuous variables. Categorical variables were described as frequency (percentage), and multiple group comparisons were performed using chi-square test or Fisher’s exact test (for small sample sizes). To evaluate group differences in main variables while controlling for potential confounding factors, we performed covariate analysis using linear regression models, with age, body mass index (BMI), and gender as covariates. Model significance was assessed using t-tests for regression coefficients, with P≤0.05 considered statistically significant. Results Baseline demographic data of all study population A total of 312 patients with pulmonary hypertension were identified in this retrospective study conducted at 3,658 meters altitude on the Tibet Plateau. The study population had a mean age of 60±14 years, with 164 males (52.6%), predominantly Tibetan ethnicity (94.6%). Smoking prevalence was 31.4% (n=98) and hypertension was the most common comorbidity at 41.0% (n=128), body mass index of 23.8±4.3 kg/m2 (Table 1). Table 1Baseline demographic data of all study population (n=312)CharacteristicsValuesAge (years)60±14Male164 (52.6)Tibetan295 (94.6)Altitude (m)3,865±409Smokers98 (31.4)Drinkers89 (28.5)BMI (kg/m2)23.8±4.3Hypertension128 (41.0)Diabetes9 (2.9)Data are presented as mean ± standard deviation or n (%). BMI, body mass index. Baseline demographic data of all study population (n=312) Data are presented as mean ± standard deviation or n (%). BMI, body mass index. Distribution of PH by clinical classification and etiology According to the WHO criteria, disease etiologies were stratified into five clinical groups. Group 3 was the largest cohort, consisting of 206 patients (66.0%). It was mainly dominated by COPD/pulmonary emphysema (97 cases, 31.1%) and HAPH (92 cases, 29.5%), as well as other lung diseases (11 cases, 3.5%), restrictive lung disease (4 cases of Interstitial Pneumonia and 1 cases of Sarcoidosis, 1.6%), and obstructive sleep apnea syndrome (1 case, 0.3%).Group 2 included 50 patients (16.0%), which was dominated by heart failure (28 cases, 9.0%) and valvular heart disease (22 cases, 7.1%). Group 1 comprised 40 patients (12.8%), mainly including congenital heart disease (25 cases, 8.0%), connective tissue diseases (14 cases, 4.5%), and portal hypertension (1 case, 0.3%). Group 5 contained 9 patients (2.9%), with hyperthyroidism (6 cases, 1.9%) and renal failure (3 cases, 1.0%) as the primary causes. Group 4 represented chronic thromboembolic pulmonary hypertension, with 7 cases (2.2%) (Figures 1,2). Categories of pulmonary hypertension at high altitude (n=312). Etiology of pulmonary hypertension at high altitude. COPD, chronic obstructive pulmonary disease; HAPH, high altitude pulmonary hypertension. Demographic characteristics, lifestyle, laboratory and echocardiographic parameters across groups Demographic characteristics and lifestyle: significant differences were observed across the groups in terms of age, gender,and smokers (all P<0.05). Group 3 had the highest proportion of males (62.1%), the oldest age (63±13 years), and the highest smoking rate (39.8%). Group 1 had the youngest average age (48±16 years). All groups predominantly consisted of Tibetan ethnicity (93.2–100%), with no significant difference (P>0.05). There were no significant differences among the groups in terms of BMI, altitude of residence and alcohol history (P>0.05), However, Group 3 had the highest body weight (66±14 kg, P<0.05). Vital signs: significant differences were observed in systolic and diastolic blood pressure across the groups (P<0.001). Group 5 had the highest average systolic blood pressure (140±32 mmHg), while Group 3 had the highest diastolic pressure (85±17 mmHg). Oxygen saturation (SpO2) was lowest in Group 4 (74%±11%, P=0.001). Laboratory parameters: significant differences were noted in red blood cell (RBC) count, hematocrit (HCT), and hemoglobin (HGB) across the groups (all P<0.001). Group 3 had the highest values for RBC (6.1±1.2×1012/L), HCT (54%±11%), and HGB (173±37 g/L). Echocardiographic parameters: the left ventricular end-diastolic diameter and mitral regurgitation velocity were highest in Group 2 [51 (42, 60) mm; 4.78 (3.54, 5.10) m/s], with the lowest left ventricular ejection fraction [55% (42%, 70%)]. Pulmonary artery systolic pressure and tricuspid regurgitation velocity showed significant differences across the groups (P<0.05). No significant differences were observed for other echocardiographic parameters (P>0.05). (Tables 2,3). Table 2Demographic characteristics, lifestyle and laboratory parameters across groupsParametersGroup 1 (n=40)Group 2 (n=50)Group 3 (n=206)Group 4 (n=7)Group 5 (n=9)PDemographic characteristics Age (years)48±1659±1363±1356±859±13<0.001 Male12 (30.0)21 (42.0)128 (62.1)2 (28.6)1 (11.1)<0.001 Tibetan40 (100.0)47 (94.0)192 (93.2)7 (100.0)9 (100.0)<0.001Lifestyle and behavioral factors Altitude (m)3,963±5673,745±3913,879±3743,865±2663,769±4450.12 Smokers4 (10.0)9 (18.4)82(39.8)1 (14.3)2 (22.2)<0.001 Drinkers5 (12.5)13 (26.5)68 (33.0)1 (14.3)2 (22.2)0.09Anthropometric indices SBP (mmHg)114±15122±25130±26110±16140±32<0.001 DBP (mmHg)71±1382±1785±1782±1583±23<0.001 SpO2 (%)84±881±979±1074±1188±40.001Laboratory parameters RBC (1012/L)5.2±1.65.3±1.06.1±1.25.9±1.34.8±1.6<0.001 HCT (%)45±1346±1054±1151±1239±13<0.001 HGB (g/L)143±45149±32173±37160±40122±40<0.001Data are presented as mean ± standard deviation or n (%). Group 1, pulmonary arterial hypertension; Group 2, pulmonary hypertension due to left heart disease; Group 3, pulmonary hypertension due to lung diseases and/or hypoxia; Group 4, chronic thromboembolic pulmonary hypertension; Group 5, pulmonary hypertension with unclear and multifactorial mechanisms. DBP, diastolic blood pressure; HCT, hematocrit; HGB, hemoglobin; RBC, red blood cell; SBP, systolic blood pressure; SpO2, pulse oxygen saturation. Demographic characteristics, lifestyle and laboratory parameters across groups Data are presented as mean ± standard deviation or n (%). Group 1, pulmonary arterial hypertension; Group 2, pulmonary hypertension due to left heart disease; Group 3, pulmonary hypertension due to lung diseases and/or hypoxia; Group 4, chronic thromboembolic pulmonary hypertension; Group 5, pulmonary hypertension with unclear and multifactorial mechanisms. DBP, diastolic blood pressure; HCT, hematocrit; HGB, hemoglobin; RBC, red blood cell; SBP, systolic blood pressure; SpO2, pulse oxygen saturation. Table 3Echocardiographic parameters across groupsCharacteristicGroup 1 (n=40) Group 2 (n=50)Group 3 (n=206)Group 4 (n=7)Group 5 (n=9)PRVID (mm)30 (26, 39)30 (26, 37)30 (26, 33)32 (27, 40)26 (19, 30)0.12LVEDD (mm)42 (38, 47)51 (42, 60)43 (40, 48)42 (38, 53)48 (42, 51)<0.001LAD (mm)32 (28, 40)42 (38, 51)33 (27, 40)43 (32, 44)31 (29, 34)<0.001sPAP (mmHg)67 (51, 85)66 (53, 83)60 (45, 75)76 (71, 93)55 (51, 58)0.02MRV (m/s)3.30 (2.60, 4.20)4.78 (3.54, 5.10)3.30 (2.70, 4.35)3.95 (2.03, 4.85)4.15 (3.90, 4.47)<0.001TRV (m/s)3.70 (3.17, 4.30)3.47 (3.04, 4.03)3.60 (3.30, 4.10)4.00 (3.90, 4.50)3.30 (3.19, 3.40)0.02MPAD (mm)23.0 (19.0, 29.5)23.0 (20.0, 27.0)23.0 (20.0, 27.0)23.0 (20.0, 31.0)21.0 (19.0, 22.0)0.60IVST (mm)9.00 (8.00, 10.00)9.00 (8.00, 10.00)10.00 (8.00, 10.00)10.00 (9.00, 10.00)9.50 (8.00, 11.50)0.30LVEF (%)66 (61, 71)55 (42, 70)67 (61, 73)70 (45, 71)64 (62, 69)0.007Data are presented as median (P25, P75). Group 1, pulmonary arterial hypertension; Group 2, pulmonary hypertension due to left heart disease; Group 3, pulmonary hypertension due to lung diseases and/or hypoxia; Group 4, chronic thromboembolic pulmonary hypertension; Group 5, pulmonary hypertension with unclear and multifactorial mechanisms. IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MPAD, main pulmonary artery diameter; MRV, mitral regurgitation velocity; RVID, right ventricular internal diameter; sPAP, systolic pulmonary artery pressure; TRV, tricuspid regurgitation velocity. Echocardiographic parameters across groups Data are presented as median (P25, P75). Group 1, pulmonary arterial hypertension; Group 2, pulmonary hypertension due to left heart disease; Group 3, pulmonary hypertension due to lung diseases and/or hypoxia; Group 4, chronic thromboembolic pulmonary hypertension; Group 5, pulmonary hypertension with unclear and multifactorial mechanisms. IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MPAD, main pulmonary artery diameter; MRV, mitral regurgitation velocity; RVID, right ventricular internal diameter; sPAP, systolic pulmonary artery pressure; TRV, tricuspid regurgitation velocity. Comparative epidemiological characteristics: COPD vs. HAPH COPD and HAPH collectively accounted for 60.6% of all enrolled patients and were the two predominant etiologies within Group 3. Therefore, a detailed comparative epidemiological analysis was performed between COPD and HAPH. Demographic characteristics: patients with COPD were significantly older than those with HAPH, with a median age of 70 years (IQR, 62–75 years) versus 59 years (IQR, 48–69 years) (P<0.001). Gender distribution was similar between the two groups, with a male predominance of 63% in both (P>0.9). The proportion of Tibetan ethnicity was higher in the COPD group (97% vs. 89%, P=0.01). Lifestyle and behavioral factors: patients in the HAPH group resided at a significantly higher mean altitude than those in the COPD (3,820 vs. 3,660 m, P=0.02). The smokers was higher in the COPD group than in the HAPH (46% vs. 34%, P=0.07). No significant differences were observed between the two groups in BMI, SBP, DBP, or SpO2 (all P>0.05). Clinical symptoms: the prevalence of dyspnea and cough was significantly higher in the COPD group than in the HAPH (P<0.005). There were no significant intergroup differences in fatigue or chest tightness. Laboratory and echocardiographic parameters: levels of total bilirubin, direct bilirubin, and fasting blood glucose were significantly higher in the HAPH group than in the COPD group (TBIL: 28 vs. 21 µmol/L, P=0.006; DBIL: 11 vs. 5 µmol/L, P<0.001; fasting blood glucose: 5.34 vs. 4.69 mmol/L, P=0.01). Platelet count was significantly lower in the HAPH group (124×109/L vs. 160×109/L, P=0.01). No significant differences were found in red blood cell count, hemoglobin, or hematocrit between the two groups (all P>0.05). After HCT-based correction sPAP in patients with HAPH, the corrected sPAP was significantly lower than that in the COPD group [51 (42, 69) mmHg vs. 64 (48, 80) mmHg, P=0.004], In addition, among patients with HAPH, after HCT-based correction, 41 cases had sPAP below 50 mmHg. There were no significant intergroup differences in other echocardiographic parameters (Table 4). Table 4Comparative epidemiological characteristics: COPD vs. HAPHCharacteristicCOPD (n=97)HAPH (n=92)PDemographic characteristics and lifestyle Age (years)70 (62, 75)59 (48, 69)<0.001 Male61 [63]58 [63]>0.90 Tibetan94 [97]82 [89]0.01 Altitude (m)3,660 (3,660, 3,897)3,820 (3,660, 4,470)0.02Laboratory and echocardiographic parameters PLT (109/L)160 (111, 207)124 (86, 167)0.01 TBIL (μmol/L)21 (13, 32)28 (16, 45)0.006 DBIL (μmol/L)5 (3, 13)11 (6, 21)<0.001 FBG (mmol/L)4.69 (4.19, 5.65)5.34 (4.44, 6.51)0.01 RVID (mm)28 (25, 32)30 (27, 33)0.20 LVEDD (mm)43 (39, 48)44 (40, 49)0.40 LAD (mm)32 (26, 41)33 (29, 39)0.06 sPAP (mmHg)64 (48, 80)51 (42, 69)0.004 TRV (m/s)3.70 (3.10, 4.20)3.60 (3.40, 4.07)0.60 MPAD (mm)22.0 (20.0, 26.0)23.0 (20.0, 28.0)0.60 IVST (mm)9.00 (8.00, 10.00)10.00 (8.00, 11.00)0.06 LVEF (%)67 (62, 73)67 (58, 73)0.70Data are presented as median (P25, P75) or n [%]. COPD, chronic obstructive pulmonary disease; DBIL, direct bilirubin; FBG, fasting blood glucose; HAPH, high altitude pulmonary hypertension; IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MPAD, main pulmonary artery diameter; MRV, mitral regurgitation velocity; PLT, platelet count; RVID, right ventricular internal diameter; sPAP, systolic pulmonary artery pressure; TBIL, total bilirubin; TRV, tricuspid regurgitation velocity. Comparative epidemiological characteristics: COPD vs. HAPH Data are presented as median (P25, P75) or n [%]. COPD, chronic obstructive pulmonary disease; DBIL, direct bilirubin; FBG, fasting blood glucose; HAPH, high altitude pulmonary hypertension; IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MPAD, main pulmonary artery diameter; MRV, mitral regurgitation velocity; PLT, platelet count; RVID, right ventricular internal diameter; sPAP, systolic pulmonary artery pressure; TBIL, total bilirubin; TRV, tricuspid regurgitation velocity. Discussion In the present study, a more comprehensive inclusion criterion was adopted, covering all five groups of pulmonary hypertension in the WHO classification system. Unlike previous studies that mostly focused on Group 1 PH, especially the epidemiology, pathophysiological mechanisms, and response to targeted therapy of idiopathic pulmonary arterial hypertension (IPAH) (19), this study fills the research gap of PH in high-altitude environments. The results showed that Group 3 PH was the most common type in high-altitude regions, followed by Group 2, Group 1, Group 5, and Group 4. The main etiologies were COPD/pulmonary emphysema, HAPH, and heart failure. This study systematically clarifies the clinical classification characteristics and etiological composition of PH in high-altitude regions. Our findings revealed that Group 3 was overwhelmingly predominant in high-altitude areas, accounting for 66.03%, which was distinctly different from the epidemiological pattern in low-altitude regions where Group 2 predominates (20). The 2015 European Society of Cardiology (ESC) guidelines also indicated that Group 2 exhibits the highest prevalence among the general population worldwide (21), and this distribution pattern is consistent with the findings reported in plain regions of China and most global studies. In addition, rheumatic heart disease and HIV infection remain the major etiologies of PH in low- and middle-income countries (22,23). The interregional differences in PH classification and etiology are collectively affected by multiple confounding factors, including altitude, ethnicity, medical service capacity, study design, detection modalities, and diagnostic classification criteria. Lei et al. (10) compared and analyzed the clinical characteristics of patients with PH in plain and high-altitude regions of China, The results verified that Group 2 (left heart disease-related) PH accounted for the largest proportion in plain areas, while Group 3 prevailed in high-altitude areas, which was highly consistent with the findings of this study. It further suggests that altitude is a crucial decisive factor influencing the etiological distribution of PH. In the current study, COPD and HAPH were the major etiologies of Group 3 PH, Stratified comparison between the two etiological subgroups demonstrated that patients in the HAPH group had a higher average residential altitude (3,820 vs. 3,660 m), along with significantly increased levels of serum total bilirubin, direct bilirubin and fasting blood glucose, which indicates that metabolic disorders may exert an essential effect on the onset and progression of HAPH. Moreover, the platelet count in the HAPH group was significantly lower than that in the COPD group (124×109/L vs. 160×109/L). Such difference is closely correlated with physiological adaptive changes of blood in high-altitude environments, reflecting the adaptive responses of the hematological system to long-term high-altitude exposure. Changes in these metabolic and hematological parameters offer valuable evidence for further exploring the clinical characteristics of HAPH. This study also observed that the smoking rate of the HAPH group was lower than that of the COPD group (34% vs. 46%), but still higher than that of other groups, implying that smoking may be a potential risk factor for HAPH. Smoking not only destroys lung parenchyma by triggering airway inflammation but also directly damages pulmonary vascular endothelial function via harmful components including nicotine, which synergizes with hypoxia to promote the occurrence and development of PH (24). In conclusion, the above findings further illustrate the unique influence of high-altitude environments on HAPH patients, and provide reliable evidence for the formulation of targeted prevention and treatment strategies for HAPH in clinical practice. In high-altitude environments, the effects of chronic hypoxia and COPD on the pulmonary circulation are intertwined and difficult to completely distinguish. Long-term high-altitude exposure induces hypoxic pulmonary vasoconstriction (HPV), which serves as the core pathological basis for the development and progression of HAPH (25,26). Meanwhile, patients with COPD inherently suffer from pulmonary parenchymal destruction and reduced vascular beds, superimposed high-altitude hypoxic stimulation further activates HPV, accelerates pulmonary vascular remodeling, aggravates hypoxemia, and consequently increases right ventricular afterload. Therefore, the pathogenesis of COPD-associated PH in high-altitude regions stems from the synergistic injury mediated by long-term hypoxic exposure and chronic pulmonary diseases, rather than the independent action of a single factor. Following the WHO clinical classification criteria for PH, this study categorized enrolled cases based on background diseases. The diagnosis of HAPH requires the exclusion of secondary pathogenic factors such as COPD; nevertheless, the hypoxic contributions of the two conditions cannot be fully separated at the pathophysiological level. This indicates that simple etiological classification has certain limitations in high-altitude settings, and we acknowledge that this classification framework cannot completely eliminate the confounding effects induced by chronic high-altitude hypoxia. Future studies should adopt multi-dimensional approaches, including RHC, pulmonary function assessment and molecular biomarker detection, to quantify the independent contribution of chronic hypoxia to different subtypes of PH. No cases of idiopathic pulmonary arterial hypertension (IPAH) were identified in the present study. Although this finding appears unexpected, it is consistent with epidemiological evidence, as a rare disease requiring an exclusive diagnosis, IPAH has a global prevalence of only approximately 5.9 per million population (27). In addition, this was a single-center retrospective study that only enrolled inpatients. Early-stage IPAH patients usually present with non-specific symptoms such as exertional dyspnea and may not seek medical attention or be hospitalized in a timely manner. Furthermore, the present study found that the male-to-female ratio of PH patients was 1.1:1, with a male predominance. Although previous studies have shown that the prevalence of PH is higher in females than in males at low altitudes, which may be related to the higher incidence of etiologies causing PH such as rheumatic heart valve disease and connective tissue disease in females (28,29). However, in high-altitude regions, males are more susceptible to chronic high-altitude sickness (30), Moreover, due to the higher smoking rate and long-term exposure to hypoxic environments among males, they are more likely to develop COPD-related PH, resulting in a relatively higher proportion of male patients. The present study found that hemoglobin, hematocrit, and red blood cell count were significantly higher in Group 3 patients than in the other groups. This finding has clear pathophysiological significance. Chronic hypoxic exposure stabilizes hypoxia-inducible factor (HIF), activates the erythropoietin (EPO) signaling pathway, and stimulates the proliferation of erythroid progenitor cells in the bone marrow, leading to compensatory erythrocytosis (25), This physiological adaptation is common among residents at high altitudes and may represent a physiological response to hypoxic environments. Prolonged high-altitude exposure increases blood viscosity, which may contribute to the development of PH (31,32), PVR is linearly correlated with blood viscosity and curvilinearly correlated with hemoglobin or hematocrit (17). Accordingly, the polycythemic state in high-altitude populations interferes with the detection results of pulmonary arterial pressure. Gargani et al. found that after hematocrit correction in high-altitude residents, the pulmonary artery pressure-blood flow relationship showed no significant difference from that in low-altitude populations (33). Soria et al. also pointed out that pulmonary hypertension is rarely diagnosed in healthy high-altitude individuals, and most mild elevations in pulmonary arterial pressure represent physiological changes induced by hypoxia (34). After hematocrit correction in our HAPH patients, the sPAP decreased from 63 (56, 75) to 51 (42, 69) mmHg. This indicates that the elevated pulmonary artery pressure is partially attributed to increased blood viscosity caused by polycythemia, rather than being entirely due to pathological increases in PVR. Limitations of this study: (I) the single-center retrospective design may lead to selection bias. (II) The diagnosis of HAPH in this study was established based on the 2004 echocardiographic diagnostic criteria applicable to high-altitude populations, without RHC data, which is inconsistent with the 2022 ESC/ERS guidelines. Nevertheless, as a noninvasive modality, transthoracic Doppler echocardiography has been widely used in clinical screening and disease assessment due to its convenience and favorable reproducibility (35). Both at high and low altitudes, pulmonary artery pressure estimated by echocardiography has been verified by invasive measurement methods, and noninvasive and invasive measurements present good consistency in population-based comparisons (36,37). Taking full advantage of the above merits, this study adopted transthoracic Doppler echocardiography for the diagnosis of PH patients in high-altitude areas. (III) Measured data regarding PVR, CO, and PAWP were absent in this study. Therefore, standardized normal CO (4.5 L/min) and PAWP (10 mmHg), rather than individual in vivo measurements, were adopted for sPAP correction, which is an inherent limitation of the current research. Further studies are required to conduct systematic hematocrit correction on pulmonary hemodynamic parameters among high-altitude populations, so as to precisely evaluate the actual prevalence and disease severity of HAPH. (IV) In addition to hypoxia, pulmonary vascular function is also affected by low temperature. The Xizang Autonomous Region features a low annual average temperature and long winters. Chronic cold exposure may independently affect pulmonary vascular function through sympathetic activation and the endothelin-1 pathway, potentially exerting a synergistic effect with hypoxic pulmonary vasoconstriction (38). Relevant data on cold exposure were not systematically collected in this retrospective study. Future prospective researches should incorporate environmental temperature, ozone and other variables to assess the independent contribution of environmental factors to high-altitude PH. In conclusion, the present study systematically clarifies the clinical classification and etiological distribution of patients with PH in high-altitude regions. It reveals that Group 3 is the main type of PH in high-altitude environments, with COPD/pulmonary emphysema and HAPH as the primary etiologies. The findings of this study not only enrich the disease spectrum of PH but also lay a theoretical foundation for formulating prevention and treatment strategies for PH in high-altitude regions. Conclusions Group 3 is the most common type of pulmonary hypertension in hospitalized patients in high-altitude areas, with the main etiologies being COPD/pulmonary emphysema and HAPH. Supplementary The article’s supplementary files as Acknowledgments We extend our gratitude to the Xizang Autonomous Region People’s Hospital Ethics Committee for their review and approval of this research. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Medical Ethics Committee of Xizang Autonomous Region People’s Hospital (No. ME-TBHP-25-KJ-050) and individual consent for this retrospective analysis was waived. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0412/rc Funding: This study was supported by the Science and Technology Department of Xizang, China (grant Nos. XZ202401JD0013 and XZ202201ZY0018G). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0412/coif). The authors have no conflicts of interest to declare. Data Sharing Statement Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0412/dss References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0412/prf Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0412/dss